

MiY^QSMART iQ

9 out of 10 children showed
no clinically relevant myopia progression*
in the first 12 months of wear^{1,2}



Raising the bar in myopia control

This brochure is intended for Eye Care Professionals only.

HOYA

Improve life through vision

An evolved approach to myopia control

Years of research and clinical experience have fundamentally changed the way we manage childhood myopia. Today, myopia management has become a major focus of innovation in pediatric eye care, enabling earlier intervention and more effective outcomes for children. Acting early is no longer optional — it is essential.

A decade of learning

With over 100 peer-reviewed papers³ on D.I.M.S. Technology, HOYA has built a strong evidence-based myopia management offering, continuously refining its approach.

A more precise approach to patient care

Myopia progression varies between children. Early identification of rapid progression supports timely intervention and closer monitoring, with the potential to improve long-term outcomes.

Thoughtful innovation driven by insight

Insights from our publications have highlighted the need for a dedicated solution to address myopia progression profiles that may not have been previously sufficiently covered.

REDEFINING what's possible in myopia control

HOYA's most advanced myopia control spectacle lens marks a new era for D.I.M.S. Technology by combining it with a new Triple Enhanced Design (DIMS TED), delivering stronger outcomes for children who need more

Since 2018, more than 15 million MiYOSMART spectacle lenses have been dispensed across 50+ countries worldwide⁴, establishing MiYOSMART as a trusted myopia control solution. MiYOSMART iQ builds on this foundation, integrating insights from a long-term research partnership with The Hong Kong Polytechnic University and a broad body of published scientific evidence.

D.I.M.S. Technology Built on an award-winning platform



Gold Prize, Grand Award & Special Gold Award Winner, International Exhibition of Inventions of Geneva 2018



Silmo d'Or Award in Vision category, Silmo Paris Optical Fair 2020

9 out of 10 children showed **no clinically relevant myopia progression*** within the first 12 months of wear^{1,2}

Triple Enhanced Design (TED)

Building on the proven foundation of D.I.M.S. Technology, MiYOSMART iQ introduces a more advanced approach to myopia control.

Three critical design enhancements have been introduced to improve myopia control performance.

Elevated with the Triple Enhanced Design, D.I.M.S. Technology features include:

Activated — Defocus segments closer to the center


Defocus segments positioned closer to the geometric center of the spectacle lens, intended to continuously activate the near-peripheral retina identified as the region most responsive to myopic defocus.^{5,6}

Powerful — Higher defocus power

Enables a stronger myopic defocus signal to the near-peripheral retina.

Extended — Larger treatment zone

More defocus segments to ensure extensive coverage of the child's peripheral visual field with myopic defocus signal, even for larger frames.




MiYOSMART just got smarter

Continuous activation of the "Smart Zone"[†]

The near-peripheral retina was found to be highly responsive to myopic defocus signals and can play a pivotal role in regulating eye growth mechanisms, influencing long-term refractive development.^{4,5}

Designed to activate. Continuously.

The DIMS TED spectacle lens, due to its smarter design, intends to continuously activate the "Smart Zone", maximizing myopia control effectiveness.



[†]"Smart Zone" is a marketing term used by HOYA when referring to a near-peripheral retinal zone shown to respond to myopic defocus. It is not a standard clinical or scientific term.



A breakthrough in clinical performance

MiYOSMART iQ delivers the strongest clinical results to date for D.I.M.S. Technology and has been evaluated in a randomised controlled clinical trial (RCT) in children aged 4 to 12 years.^{6,7}

These outcomes represent the most effective myopia control results seen so far with D.I.M.S. Technology spectacle lenses.



9 out of 10 children showed no clinically relevant myopia progression* at 12 months¹⁻³



Minimal eye growth on average¹⁻³




HOYA's first spectacle lens with reported clinical evidence for effective control of myopia progression from the age of 4 years, as a monotherapy.¹⁻³


Changes in the SER and AL across three lens groups in children aged 4-12

Myopia Progression (Cycloplegic SER, D) over first 12-month period

Change in SER (D) over 12 months: Single Vision (SV) spectacle lens vs MiYOSMART spectacle lens vs MiYOSMART iQ spectacle lens (p < 0.001)
Mean difference in SER - MiYOSMART iQ compared with SV: 0.58±0.08D, p<0.001 (Bonferroni).



"DIMS TED produced the strongest normalization effect, with axial elongation not merely approaching but falling below the AMMC-defined physiological growth range, effectively neutralizing myopic axial growth in the past."



Prof. Hakan Kaymak

Professor of Universität des Saarlandes and leading researcher at the Internationale Innovative Ophthalmochirurgie in Düsseldorf, Germany

Clear and comfortable vision for everyday life

MiYOSMART iQ spectacle lenses are now available with an optimized aspherical backside design, taking optical quality to the next level.

Powered by FreeForm technology, thousands of data points are used to meticulously shape the back surface of the lens through precise three-dimensional calculations. This intelligent optimization results in superior optical accuracy, reduced optical aberrations, and a thinner, flatter lens profile - combining performance and aesthetics into one smart solution.

1. Enhanced clarity

Using FreeForm technology, prescription values are optimized on the back surface of the lens to ensure superior visual performance in everyday viewing situations, no matter where children look.

MiYOSMART iQ^{TF} optical design is engineered to keep up by reducing optical aberrations, offering sharper image quality while delivering clear vision across the lens, supporting daily activities with confidence.

2. Refined aesthetics

How spectacles look and feel truly matters to children,⁸ especially when their prescriptions increase. MiYOSMART iQ^{TF} spectacle lenses are designed with flatter lens curvatures, which significantly improve the lens aesthetics by reducing edge thickness.

With an **edge thickness reduced by up to 10%** compared to a standard spectacle lens,⁹ MiYOSMART iQ^{TF} offers improved frame compatibility and a more aesthetic appearance. The spectacle lenses look lighter, feel more comfortable and fit more naturally - helping young patients feel confident wearing their glasses every day.



Advanced performance. Two ways.

Designed to fit seamlessly into daily life.



MiYOSMART iQ Clear

Clinically proven, optically excellent, and indistinguishable from a standard single vision corrective lens.



MiYOSMART iQ Chameleon

Adaptive tinting for children who spend time both indoors and outdoors, offering the same advanced myopia control with additional UV protection and visual comfort in changing light conditions.

Availability table

	Features Triple Enhanced Design for maximized myopia control effectiveness	FreeForm Technology	Coating			Tint options		
			STX	S.P.A.R.K.	Full Control coating upgrade	Clear	Chameleon	Sunbird
MiYOSMART iQ	✓	✓		✓	✓	✓	✓	
MiYOSMART			✓		✓	✓	✓	✓

MiYOSMART iQ	
Lens Diameter (mm)	Combined prescription (SPH/-CYL)
	Minus power range
75	Sph 0.00; -8.00 / Cyl up -4.00
70	Sph -8.00; -10.00 / Cyl up -4.00
65	Sph -10.00; -11.50 / Cyl up -4.00
60	Sph -11.50; -13.00 / Cyl up -4.00

MiYOSMART iQ ^{TF}	
Lens Diameter (mm)	Combined prescription (SPH/-CYL)
	Minus power range
75	Sph 0.00; -8.00 / Cyl up -4.00
70	Sph -8.00; -10.00 / Cyl up -4.00
65	Sph -10.00; -11.50 / Cyl up -4.00
60	Sph -11.50; -13.00 / Cyl up -4.00

Supporting you at every step



Step 1: Assessment

Any child with progressing myopia from age 4, including those with inadequate existing myopia management treatment.



Step 2: Fitting

Ensure optimal centration for maximum treatment effectiveness with the visuReal MoveAI Kids Module, HOYA's AI-powered centration tool specifically developed for paediatric myopia management lenses. Confirm frame size compatibility — the extended 41mm treatment zone supports a wide range of children's frames.



Step 3: Follow-up

Schedule follow-up within 6 months. Monitor axial length and myopia progression. Use results to reinforce compliance and guide discussions with parents.

HOYA provides training, webinars, and resources to support confident prescribing. Contact your HOYA representative for access to the full MiYOSMART iQ professional toolkit.

MiYOSMART iQ supports both the child and the Eye Care Professional. A streamlined clinical workflow and dedicated tools make integration into your practice simple.

Built for childhood

MiYOSMART iQ with S.P.A.R.K. Coating


This new protective coating is **Scratch** resistant, gives them the **Protection** they need, uses **Advanced** technologies and benefits and is **Ready for Kids** (S.P.A.R.K.).

Children get up to all sorts of adventures, rarely pausing to wipe their eyewear clean. They need something they'll happily wear all day long, that keeps up with their active lifestyle while delivering effective myopia control.

Built with kids in mind, tailored for the long run.

Introducing S.P.A.R.K., HOYA Vision Care's advanced protective coating for MiYOSMART iQ spectacle lenses.

Designed with children in mind and built for long-term wear, it makes MiYOSMART iQ easy and comfortable to wear as an integrated multi-layered coating.



Enhanced scratch resistance

50% more scratch-resistant than the previous generation,¹² helping protect lenses from everyday wear and handling.



Resistance to smudges, dust, and water

Repels fingerprints and dust, while offering water resistance 5 x greater than the previous MiYOSMART generation.^{12,13}



Long-lasting cleanability

Designed to maintain easy-to-clean performance, even after nearly 3 years of daily wiping.^{12,13}



Clear, comfortable vision

Supports high light transmission while reducing glare and reflections for consistent visual clarity.¹⁴



UV protection

Blocks 100%¹³ of harmful UV rays from the front surface and helps reduce UV exposure from the back of the lens.

MiYOSMART iQ redefines what is possible

Elevates the standard of care

9 out of 10 children showed no clinically relevant myopia progression* in the first 12 months of wear.^{1,2}

Built on over a decade of clinical expertise

Developed through sustained scientific research, D.I.M.S. Technology is backed by 100+ peer-reviewed publications,³ 8 years of long-term data, and an ongoing partnership with The Hong Kong Polytechnic University.

Moving closer to effective myopia control

Early results are highly promising. As data and global adoption continue to grow, MiYOSMART iQ represents a meaningful step towards reducing the impact of progressive myopia on children's vision.

Let's raise the bar in myopia control



MiYOSMART iQ

Disclaimers

MiYOSMART iQ has not been approved for myopia control in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.

MiYOSMART spectacle lenses may not be able to address individuals' conditions due to natural deficiencies, illness, pre-existing medical conditions and/or advanced age of consumers. The information contained herein is general information and is not intended to constitute medical advice.

This brochure includes recommendations for Eye Care Professionals. The Eye Care Professional is responsible

for ensuring that the recommended procedure is allowed to be conducted in the country where they practice. Suitability of each recommended procedure for individual patients should be evaluated by the Eye Care Professional based on their professional judgment.

*Clinically relevant myopia progression defined as Spherical Equivalent Refraction change equal to or superior to $-0.50D$ over 12 months of wear. Outcomes for myopic children aged 4 to 12 years. They may vary per age group and other parameters at the start of MiYOSMART iQ treatment.

References

1. Tse D.Y., Hon Y., Chun R. K., Leung T. W., Leung D. K. Y., To C. H., Lam C SY. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle lens with Triple Enhanced Design: 12-month randomized controlled trial. Abstract 2523, ARVO 2026 Annual Meeting, Denver, USA. <https://eppro02.ativ.me/web/index.php?page=IntHtml&project=ARVO26&id=4486941> (accessed date 03.04.2026)
2. HOYA data on file. HOYA MiYOSMART iQ spectacle lens clinical outcomes. 04/2026.
3. Based on the number of publications in peer-reviewed publications according to HOYA's data on file as of Nov 25.
4. HOYA data on file. MiYOSMART spectacle lens commercial data. 04/2026.
5. Smith III EL, Arumugam B, Hung LF, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. *Vision Res.* 2020;177:32-40. DOI: 10.1016/j.visres.2020.08.003.
6. Swiatczak B, Scholl HPN, Schaeffel F. Retinal 'sweet spot' for myopia treatment. *Sci Rep* 14, 26773 (2024). <https://doi.org/10.1038/s41598-024-78300-x>
7. Tse DYY, Chun RKM, Hon Y, et al. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Triple Enhanced Design Spectacle Lenses. The 41st Asia-Pacific Academy of Ophthalmology Congress, 2026. <https://2026.apaophth.org/abstract/?code=205567>. Accessed 12 Jan 2026. Peer-reviewed publication will follow.
8. Eyewear Market Size, Share & Trends Analysis Report." Grand View Research, 2025, <https://www.grandviewresearch.com/industry-analysis/eyewear-industry> [Accessed 24 Apr. 2026].
9. HOYA data on file. 04/2026. All edge reduction percentages are calculated at a 65 mm diameter, comparing spherical and aspheric designs, with a maximum value of 10%. (Without providing edge thickness values.)
10. HOYA data on file. Myopia Control Efficacy of Second-generation Defocus Incorporated Multiple Segments Spectacle Lenses on Fast Progressing Myopes: A Randomised Controlled Trial: Summary of 12-month analysis on complete cases. 01/2026.
11. Vlasak N. et al. Eight years of performance of defocus incorporated multiple segments (DIMS) spectacle lenses: User experience and myopia management outcomes. Rapid Fire Session VII: Myopia. EAOO 2025, Ljubljana, Slovenia.
12. HOYA data on file. MiYOSMART iQ S.P.A.R.K. coating technical results. 05/2026.
13. HOYA data on file. Product assessment report – "STX MiYOSMART Green PAR. 06/2025.
14. HOYA data on file. MiYOSMART iQ S.P.A.R.K. coating technical data. 04/2026. Compliance with ISO 8980-3:2022.
15. International Myopia Institute (IMI) Facts and Findings: 2023. Available from: <https://myopiainstitute.org/myopia-infographics/> (Last accessed: July 2025)



For more information about MiYOSMART iQ, scan the QR code or visit **hoyavision.com**